Literature DB >> 6479015

Naltrexone treatment of heroin addiction: one-year follow-up.

B A Judson, A Goldstein.   

Abstract

Pre-treatment characteristics and post-treatment outcome measures were compared for 40 patients who began naltrexone maintenance and 77 who did not after a 6-month period of temporary maintenance on L-alpha-acetylmethadol (methadyl acetate LAAM). Patients who chose to begin naltrexone were younger, had fewer incarcerations and fewer months incarcerated prior to LAAM treatment, had fewer opiate-free months following previous treatments, and were more likely to be of Caucasian ethnicity. One year later, significantly more patients who had received any naltrexone than those who had not were no longer in any treatment program and were opiate-free. We found no significant correlations between total duration of naltrexone-treatment and post-treatment outcome variables such as heroin use, arrests, incarcerations or enrollment in a treatment program.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6479015     DOI: 10.1016/0376-8716(84)90003-6

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  9 in total

1.  Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

Authors:  Linda Olsen; Asbjørg S Christophersen; Grete Frogopsahl; Helge Waal; Jørg Mørland
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 2.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

3.  Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Authors:  Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman
Journal:  Mol Neurobiol       Date:  2011-09-24       Impact factor: 5.590

4.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

5.  A 50-year-old woman addicted to heroin: review of treatment of heroin addiction.

Authors:  Charles P O'Brien
Journal:  JAMA       Date:  2008-07-01       Impact factor: 56.272

Review 6.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

7.  Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.

Authors:  Kenneth Blum; Marlene Oscar-Berman; John Femino; Roger L Waite; Lisa Benya; John Giordano; Joan Borsten; William B Downs; Eric R Braverman; Raquel Loehmann; Kristina Dushaj; David Han; Thomas Simpatico; Mary Hauser; Debmalya Barh; Thomas McLaughlin
Journal:  J Addict Res Ther       Date:  2013-04-23

Review 8.  Human microbiota research in Africa: a systematic review reveals gaps and priorities for future research.

Authors:  Imane Allali; Regina E Abotsi; Lemese Ah Tow; Lehana Thabane; Heather J Zar; Nicola M Mulder; Mark P Nicol
Journal:  Microbiome       Date:  2021-12-15       Impact factor: 14.650

Review 9.  Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Min Zhao; Suzanne Nielsen; Matthew Torrington; Karen Miotto
Journal:  Subst Abuse Rehabil       Date:  2011-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.